Troches offer a middle ground between topical and injectable delivery: more bioavailable than creams but less direct than injections
severe or persistent upper abdominal pain should prompt urgent medical assessment [10] [11] Dehydration and acute kidney injury (AKI): gastrointestinal fluid losses can lead to dehydration, which may precipitate AKI, particularly in those with pre-existing renal impairment or those taking nephrotoxic medicines Delayed gastric emptying: this may affect the absorption of orally administered medicines, including contraceptive pills and thyroid replacement therapy [11] Injection site reactions: redness, bruising, or discomfort at the subcutaneous injection site Heart rate changes: increases in resting heart rate have been noted with GLP-1 class agents [14] [15] Hypoglycaemia: particularly if used alongside insulin or sulphonylureas Potential pancreatitis risk: a class concern with GLP-1 receptor agonists
As expected, positive control analyses showed lower risks of major adverse cardiovascular events and major adverse kidney events among GLP-1 RA initiators relative to DPP-4i initiators, whereas negative control outcomes (glaucoma and bone fracture) did not differ between groups ( Supplementary Table 2 )
Metabolic and weight loss effects Semaglutide consistently delivers significant weight loss (up to 17%) and improves glycemic control in diabetic and non-diabetic populations
Our focus on the online GLP 1 Chicago model means accessibility meets expertise
.jpg)
